Using both familial and sporadic mouse models of malignant GAC, the effects of SMYD5 ablation were assessed in vivo by Park et al. The progression of peritoneal carcinomatosis was monitored following the genetic disruption of SMYD5, while the impact on GAC xenografts derived from patient samples and human cancer cell lines was evaluated in vitro. The gene discussed is SMYD5; the disease is cancer.